Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer

Justin R Gregg¹, Jeri Kim², Christopher Logothetis³, Sam Hanash⁴, Xiaotao Zhang⁵, Ganiraju Manyam⁶, Kenneth Muir⁷; UKGPCS Collaborative Group⁸; Graham G Giles⁹, Janet L Stanford¹⁰, Sonja I Berndt¹¹, Manolis Kogevinas¹², Hermann Brenner¹³, Rosalind A Eeles¹⁴; PRACTICAL Consortium⁸; Peng Wei⁶, Carrie R Daniel⁵

Affiliations

¹ Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jrgregg@mdanderson.org.
² Merck & Co., Kenilworth, NJ, USA.
³ Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Epidemiology, Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Biostatistics, Division of Basic Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁷ Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK; Warwick Medical School, University of Warwick, Coventry, UK.
⁸ The Institute of Cancer Research, London, UK.
⁹ Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.
¹⁰ Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA.
¹¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA.
¹² ISGlobal, Barcelona, Spain; Hospital del Mar Medical Research Institute, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain.
¹³ Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany; Division of Preventive Oncology, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany.
¹⁴ The Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK.

PMID: 35995710
PMCID: PMC9939555
DOI: 10.1016/j.euo.2022.07.008

Multicenter Study

Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer

Justin R Gregg et al. Eur Urol Oncol. 2023 Jun.

. 2023 Jun;6(3):282-288.

doi: 10.1016/j.euo.2022.07.008. Epub 2022 Aug 20.

Authors

Affiliations

¹ Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jrgregg@mdanderson.org.
² Merck & Co., Kenilworth, NJ, USA.
³ Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Epidemiology, Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Biostatistics, Division of Basic Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁷ Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK; Warwick Medical School, University of Warwick, Coventry, UK.
⁸ The Institute of Cancer Research, London, UK.
⁹ Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.
¹⁰ Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA.
¹¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA.
¹² ISGlobal, Barcelona, Spain; Hospital del Mar Medical Research Institute, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain.
¹³ Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany; Division of Preventive Oncology, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany.
¹⁴ The Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK.

PMID: 35995710
PMCID: PMC9939555
DOI: 10.1016/j.euo.2022.07.008

Abstract

Background: Coffee intake may lower prostate cancer risk and progression, but postdiagnosis outcomes by caffeine metabolism genotype are not well characterized.

Objective: To evaluate associations between coffee intake, caffeine metabolism genotype, and survival in a large, multicenter study of men with prostate cancer.

Design, setting, and participants: Data from The PRACTICAL Consortium database for 5727 men with prostate cancer from seven US, Australian, and European studies were included. The cases included had data available for the CYP1A2 -163C>A rs762551 single-nucleotide variant associated with caffeine metabolism, coffee intake, and >6 mo of follow-up.

Outcome measurements and statistical analysis: Multivariable-adjusted Cox proportional hazards models across pooled patient-level data were used to compare the effect of coffee intake (categorized as low [reference], high, or none/very low) in relation to overall survival (OS) and prostate cancer-specific survival (PCSS), with stratified analyses conducted by clinical disease risk and genotype.

Results and limitations: High coffee intake appeared to be associated with longer PCSS (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.68-1.08; p = 0.18) and OS (HR 0.90, 95% CI 0.77-1.07; p = 0.24), although results were not statistically significant. In the group with clinically localized disease, high coffee intake was associated with longer PCSS (HR 0.66, 95% CI 0.44-0.98; p = 0.040), with comparable results for the group with advanced disease (HR 0.92, 95% CI 0.69-1.23; p = 0.6). High coffee intake was associated with longer PCSS among men with the CYP1A2 AA (HR 0.67, 95% CI 0.49-0.93; p = 0.017) but not the AC/CC genotype (p = 0.8); an interaction was detected (p = 0.042). No associations with OS were observed in subgroup analyses (p > 0.05). Limitations include the nominal statistical significance and residual confounding.

Conclusions: Coffee intake was associated with longer PCSS among men with a CYP1A2 -163AA (*1F/*1F) genotype, a finding that will require further replication.

Patient summary: It is likely that coffee intake is associated with longer prostate cancer-specific survival in certain groups, but more research is needed to fully understand which men may benefit and why.

Keywords: Caffeine; Coffee; Genetic variation; Mortality; Prostatic neoplasms.

PubMed Disclaimer

Conflict of interest statement

Financial disclosures: Justin R. Gregg certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Justin R. Gregg serves on an advisory board for Bayer. The remaining authors have nothing to disclose.

References

1. Kempf K, Herder C, Erlund I, et al. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr 2010;91:950–7. - PubMed
1. Guercio BJ, Sato K, Niedzwiecki D, et al. Coffee intake, recurrence, and mortality in stage III colon cancer: results from CALGB 89803 (Alliance). J Clin Oncol 2015;33:3598–607. - PMC - PubMed
1. Liu H, Hu G-H, Wang X-C, et al. Coffee consumption and prostate cancer risk: a meta-analysis of cohort studies. Nutr Cancer 2015;67:392–400. - PubMed
1. Sachse C, Brockmöller J, Bauer S, et al. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445–9. - PMC - PubMed
1. Guest N, Corey P, Vescovi J, et al. Caffeine, CYP1A2 genotype, and endurance performance in athletes. Med Sci Sports Exerc 2018;50:1570–8. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer

Affiliations

Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical